Lee's Pharm: Lee's Pharm Signs $78.9 Million Deal for RDS Drug/Device for Pre-Term Infants

Lee's Pharm of Hong Kong entered a $78.9 million deal with Windtree Therapeutics for global rights to a therapy for respiratory distress syndrome in pre-term infants. The therapy includes Surfaxin®, a lyophilized lucinactant, and the AeroSurf non-invasive drug/device. Lee's, which had previously acquired China rights to the therapy, will be fully responsible for all costs of global development. There is no additional upfront payment, but Lee's will pay up to $78.9 million in milestones, plus royalties on sales. RDS often occurs in preterm infants if the lung is not fully developed with natural surfactant. More details....Stock Symbol: (HK: 0950)Share this with colleagues: